AI English summary of an SEC filing — figures as filed
Boston Scientific BSXThe company said on February 2, 2026 that Yoshiaki Fujimori informed it he will not stand for re-election at the 2026 Annual Meeting of Stockholders.
Key points
AI summaryThe company said on February 2, 2026 that Yoshiaki Fujimori informed it he will not stand for re-election at the 2026 Annual Meeting of Stockholders.
Boston Scientific said Fujimori has served on the Board since July 2016 and currently chairs the Risk, Science and Technology Committee.
The company said Fujimori will continue to serve as a director and in his committee roles until the 2026 Annual Meeting, and that his decision not to stand for re-election is not the result of any disagreement with the company.
It said the Board and the Nominating and Governance Committee regularly review the size and composition of the Board and will continue to evaluate whether adding directors following Fujimori's departure is in the best interest of the company.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Yoshiaki Fujimori Will Not Stand for Re-Election at 2026 Annual Meeting
The company said on February 2, 2026 that Yoshiaki Fujimori informed it he will not stand for re-election at the 2026 Annual Meeting of Stockholders.
Source · Based on the filing body and exhibits
Fujimori's Board Tenure and Committee Role
Boston Scientific said Fujimori has served on the Board since July 2016 and currently chairs the Risk, Science and Technology Committee.
Source · Based on the filing body and exhibits
Director and Committee Roles Through 2026 Annual Meeting
The company said Fujimori will continue to serve as a director and in his committee roles until the 2026 Annual Meeting, and that his decision not to stand for re-election is not the result of any disagreement with the company.
Source · Based on the filing body and exhibits
Review of Adding Directors After Fujimori's Departure
It said the Board and the Nominating and Governance Committee regularly review the size and composition of the Board and will continue to evaluate whether adding directors following Fujimori's departure is in the best interest of the company.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…